Clal Insurance’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $61.9M | Sell |
484,500
-206,500
| -30% | -$25.8M | 0.37% | 56 |
|
|
2025
Q4 | $84.3M | Buy |
691,000
+263,000
| +61% | +$30.2M | 0.54% | 43 |
|
|
2025
Q3 | $42.9M | Hold |
428,000
| – | – | 0.33% | 63 |
|
|
2025
Q2 | $35.5M | Buy |
428,000
+174,000
| +69% | +$13.9M | 0.35% | 59 |
|
|
2025
Q1 | $20.6M | Sell |
254,000
-280,000
| -52% | -$25M | 0.21% | 64 |
|
|
2024
Q4 | $48.1M | Sell |
534,000
-896,000
| -63% | -$86.8M | 0.43% | 48 |
|
|
2024
Q3 | $141M | Buy |
+1,430,000
| New | +$140M | 1.25% | 23 |
|
|
2023
Q4 | – | Sell |
-357,015
| Closed | -$26.1M | – | 142 |
|
|
2023
Q3 | $26.1M | Hold |
357,015
| – | – | 0.36% | 57 |
|
|
2023
Q2 | $29.7M | Sell |
357,015
-310,000
| -46% | -$25.9M | 0.36% | 63 |
|
|
2023
Q1 | $50.8M | Sell |
667,015
-912,985
| -58% | -$75.8M | 0.76% | 39 |
|
|
2022
Q4 | $131M | Hold |
1,580,000
| – | – | 1.97% | 17 |
|
|
2022
Q3 | $125M | Sell |
1,580,000
-862,000
| -35% | -$72.7M | 1.72% | 17 |
|
|
2022
Q2 | $181M | Buy |
2,442,000
+412,000
| +20% | +$30.9M | 2.41% | 9 |
|
|
2022
Q1 | $182M | Buy |
2,030,000
+1,182,000
| +139% | +$109M | 1.93% | 13 |
|
|
2021
Q4 | $94.9M | Buy |
848,000
+276,650
| +48% | +$33.4M | 1.03% | 28 |
|
|
2021
Q3 | $71.8M | Buy |
571,350
+111,000
| +24% | +$14.3M | 0.82% | 42 |
|
|
2021
Q2 | $62.3M | Buy |
460,350
+270,000
| +142% | +$35.5M | 0.71% | 56 |
|
|
2021
Q1 | $25.8M | Sell |
190,350
-333,500
| -64% | -$49.9M | 0.3% | 89 |
|
|
2020
Q4 | $68.9M | Sell |
523,850
-146,150
| -22% | -$18.7M | 0.94% | 41 |
|
|
2020
Q3 | $74.7M | Hold |
670,000
| – | – | 1.26% | 29 |
|
|
2020
Q2 | $75M | Sell |
670,000
-265,000
| -28% | -$26.1M | 1.49% | 19 |
|
|
2020
Q1 | $72.4M | Buy |
935,000
+874,680
| +1,450% | +$77.5M | 1.81% | 18 |
|
|
2019
Q4 | $634K | Sell |
60,320
-873,894
| -94% | -$75.6M | 0.68% | 40 |
|
|
2019
Q3 | $71.2M | Hold |
934,214
| – | – | 1.73% | 15 |
|
|
2019
Q2 | $81.9M | Buy |
934,214
+1,214
| +0.1% | +$104K | 1.88% | 16 |
|
|
2019
Q1 | $84.5M | Buy |
933,000
+333,000
| +56% | +$28.3M | 2.07% | 17 |
|
|
2018
Q4 | $43M | Hold |
600,000
| – | – | 1.12% | 27 |
|
|
2018
Q3 | $57.5M | Hold |
600,000
| – | – | 1.53% | 20 |
|
|
2018
Q2 | $57.1M | Sell |
600,000
-752,197
| -56% | -$69.1M | 1.48% | 22 |
|
|
2018
Q1 | $119M | Buy |
+1,352,197
| New | +$123M | 3.15% | 12 |
|
|
2017
Q1 | – | Sell |
-125,500
| Closed | -$7.43M | – | 78 |
|
|
2016
Q4 | $7.43M | Hold |
125,500
| – | – | 0.14% | 41 |
|
|
2016
Q3 | $8.32M | Buy |
+125,500
| New | +$7.76M | 0.19% | 49 |
|
Other funds holding XBI
Clal Insurance's XBI Position: Q1 2026 in Review
Clal Insurance reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 30% in Q1 2026, selling an estimated $25.8M and leaving 484,500 shares worth $61.9M. The position accounts for 0.37% of the portfolio, ranked #56.
Clal Insurance first reported a position in XBI in Q3 2016 and has held it in 32 quarters since. The position peaked at $182M in Q1 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Clal Insurance held 484,500 shares of State Street SPDR S&P Biotech ETF worth $61.9M as of Q1 2026.
- Clal Insurance sold 206,500 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $25.8M.
- State Street SPDR S&P Biotech ETF made up 0.37% of Clal Insurance's portfolio in Q1 2026, its #56 holding.
- Clal Insurance first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and has held it in 32 quarters since.
- Clal Insurance's State Street SPDR S&P Biotech ETF position peaked at $182M in Q1 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Clal Insurance's 13F filing for Q1 2026, filed 12 May 2026.